language_icon
EN
HI

Mankind Pharma Share price

MANKIND

2320.2

55.40 (-2.33%)
NSE
BSE
Last updated on 1 Jun, 2026 | 15:46 IST
Today's High

2408.00

Today's Low

2309.70

52 Week Low

1909.70

52 Week High

2716.50

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Mankind Pharma Chart

Mankind Pharma Share Key Metrics

Volume
2.85 L
Market Cap
95779.03 CR
LTQ@LTP
1@2320.20
ATP
2350.26
Var Margin
14.71 %
Circuit Range
2138.1-2613.1
Delivery %
66.69 %
Value
67.04 CR
ASM/GSM
No
Market Lot
1

Summary

Mankind Pharma share price is ₹2320.2 as of 2 Jun, 2026. The stock Mankind Pharma intraday movement has stayed between ₹2309.70 and ₹2408.00, while on a 52-week basis,Mankind Pharma price 52 week high is ₹2716.50 & its 52 week low is ₹1909.70.
In terms of trading activity, Mankind Pharma has recorded a volume of 285229 shares, The Mankind Pharma has a market cap of ₹412805072 CR. The stock’s Average Traded Price (ATP) stands at ₹2350.26, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹2320.20.
Mankind Pharma operates within a circuit range of ₹2138.10 – ₹2613.10, with a Value of ₹67.04 CR. The Delivery Percentage for the day is 66.69%. Additionally, Mankind Pharma currently falls under the No framework, and trades with a market lot size of 1.

Mankind Pharma Fundamentals

View More
P/E Ratio

51.32

P/B Ratio

6.02

Div. Yield

0

Sector P/E

69.53

Sector P/B

2.99

Sec. Div. Yield

0.55

Mankind Pharma Resistance and Support

Pivot 2402.53

Resistance

First Resistance

2441.86

Second Resistance

2508.13

Third Resistance

2547.46

Support

First Support

2336.26

Second Support

2296.93

Third Support

2230.66

Mankind Pharma Futures & Options

2320.2

-55.4 (-2.33%)

link_white_icon

Mankind Pharma Option Chain

View Price, OI, Greeks & More...
View All

30JUN26

2329.10

-73.50 (3.06%)

28JUL26

2324.30

-79.10 (3.29%)

25AUG26

2350.00

-63.40 (2.63%)

MANKIND|30JUN26 CE 2320.00

0.00

-49.2 (-100%)

MANKIND|30JUN26 PE 2340.00

60.25

0 (0%)

Mankind Pharma Shareholding Pattern

View More
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

72.66%

Mutual Fund

10.36%

Insurance

1.14%

Foreign Institutional Investors

10.24%

Domestic Institutional Investors

2.92%

Retail

2.68%

Others

0%

Total Promoters
MAR '26
72.66%

Mankind Pharma Corporate Actions

DateAgenda
2026-05-19Audited Results
2026-02-03Quarterly Results
2025-11-06Quarterly Results
2025-07-31Quarterly Results & Interim Dividend
2025-05-21Audited Results
2025-01-23Quarterly Results

Mankind Pharma News

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Mankind Pharma management will attend investor conferences in Mumbai on June 1 and June 2, 2026. Discussions will focus on the general business outlook, with no unpublished price sensitive information to be disclosed.
May 27 2026 16:14:36

Mankind Pharma Limited

Mankind Pharma's Q4 FY26 revenue grew 11.8% YoY to Rs.3,443 crore, with PAT rising 30.4% to Rs.559 crore. The company outlined positive outlooks for FY27, targeting double-digit growth and 25.5%-26.5% EBITDA margins.
May 26 2026 17:01:32

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Mankind Pharma's management will hold meetings with various investors in Singapore on May 25 and 26, 2026. These discussions will focus on the general business outlook, with no unpublished price sensitive information being disclosed.
May 20 2026 21:16:08

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Mankind Pharma has made available the audio recording of its investor conference call for Q4 & FY26 results. The call, held on May 20, 2026, features discussions with senior management and provides insights into the company's performance.
May 20 2026 16:06:48

Mankind Pharma Q4 revenue rises 12%; chronic therapies drive margin expansion

Mankind Pharma reported robust financial performance for Q4 FY24, with its net profit soaring by 62.3% year-on-year to ₹477 crore. The company's revenue from operations also increased by 19% to ₹2,441 crore, alongside a 400-basis-point expansion in EBITDA margin to 24.2%, primarily driven by growth in chronic therapies.
May 19 2026 20:17:11

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Mankind Pharma's Q4 FY26 revenue increased by 11.8% YoY to INR 3,443 Cr. The company's adjusted EBITDA margin expanded by 400 bps to 27.1%, reflecting strong operational performance for the quarter.
May 19 2026 20:06:12

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Change in Management

Mankind Pharma's board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director for another 5-year term. This re-appointment is effective from September 23, 2026, and is subject to shareholder approval at the upcoming AGM, ensuring continuity in leadership.
May 19 2026 19:31:16

Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026

Mankind Pharma's board approved Q4 FY26 cons. financial results, reporting revenue of ₹3,557.22 cr and net profit of ₹559.42 cr. The board also reappointed Satish Kumar Sharma as Whole-Time Director for five years and approved a ₹500 cr investment in its subsidiary, Mankind Medicare Private Limited.
May 19 2026 19:24:08

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Credit Rating

Mankind Pharma's credit ratings for Rs. 6,850 crore worth of debt instruments have been reaffirmed and assigned by ICRA. Long-term/short-term facilities and Non-convertible Debentures received [ICRA]AA+ (Stable) and [ICRA]A1+ ratings, while Commercial Paper was assigned [ICRA]A1+.
May 12 2026 18:18:22

Mankind Pharma Ltd - 543904 - Board Meeting Intimation for Inter Alia, Consider And Approve The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31, 2026 And Realignment Of Security Cover Provided In Respect Of Existing Ncds.

Mankind Pharma's Board of Directors will convene on May 19, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The agenda also includes a proposal for realignment of security cover for existing Non-Convertible Debentures following a ₹1,250 crore NCD redemption on April 16, 2026.
May 07 2026 18:48:50
Read More

Mankind Pharma Management

NamePosition
Hitesh Kumar JainCompany Secretary & Compliance Officer
Ramesh JunejaChairman
View More

Mankind Pharma FAQs

The Buying Price of Mankind Pharma share is 2320.2 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Mankind Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Mankind Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Mankind Pharma shares is 51.32. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Mankind Pharma shares is 6.02. Useful to assess the stock's value relative to its book value.

To assess Mankind Pharma’s valuation compare Sector P/E, P/B which are 69.53 & 2.99 with sector averages, along with growth rates and financial metrics.

The Market Cap of Mankind Pharma is 95779.03 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Mankind Pharma share price is 2716.50 & 1909.70. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Mankind Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost